Table of Contents Table of Contents
Previous Page  728 / 812 Next Page
Information
Show Menu
Previous Page 728 / 812 Next Page
Page Background

S724

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

EV1174

Aripiprazole once-monthly efficacy in

patients with schizophrenia. Review

M.F. Molina López

1 ,

, M.C. Cancino Botello

2

, A. Pe˜na Serrano

2

,

M.D.L.A. Canseco Navarro

2

1

Valencia, Spain

2

Hospital General Universitario de Valencia, Psiquiatría, Valencia,

Spain

Corresponding author.

Introduction

long acting injectable formulations of antipsy-

chotics are a valuable option for patients with schizophrenia,

offering continuous medication delivery and stable dosage levels.

Aripiprazole once-monthly is the first dopamine partial ago-

nist available in long acting formulation approved in Europe for

Schizophrenia with excellent results so far.

Aims

to conduct a current reviewof articles related to the use and

efficacy of Aripiprazole once monthly in patients with Schizophre-

nia.

Methods

systematic review of the literature in English using the

following keywords: “aripiprazole once-monthly”, “aripiprazole

long acting formulation”, “schizophrenia”. PubMed database.

Results

Aripiprazole once-monthly (AOM) formulation efficacy

has been proven in many studies. The importance of maintaining

an oral overlap during 14 days is highlighted in all studies that have

been reviewed in order to reach therapeutic level; therefore, it can

be used in patients with acute decompensations. Recent studies

comparing AOM versus Paliperidone Palmitate once monthly (PP)

have shown that patients with AOM had greater clinical improve-

ment and, even though both drugs were well tolerated, when

Quality of Life Style Scale was analyzed an important improvement

in empathy, sense of purpose, emotional interaction and curiosity

in the AOM group was observed.

Conclusions

long acting injectable antipsychotics increase long-

term adherence treatment and reduce risk of relapse. Because of its

unique mechanism of action, Aripiprazole once-monthly improves

positive and negative symptoms, giving the patient an opportunity

to have a better quality of life.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2159

EV1175

Pharmacological wash out for

clozapine induced tics: A case report

A. Morales-Rivero

1 ,

, M. Chavarria-Medina

2

,

C.L. Avina-Cervantes

1

1

Instituto1 Nacional de neurologia y neurocirugía, psichiatry, Mexico

City, Mexico

2

Instituto1 Nacional de neurologia y neurocirugía, Neurology,

Mexico City, Mexico

Corresponding author.

Introduction

Clozapine has been long used for the treatment-

resistant schizophrenia. Its effectiveness in the vast schizophrenia

symptoms is well established. However, its wide range of adverse

effects has limited its use.

Objectives/aims

To present a new strategy in order to continue

with clozapine treatment despite extrapyramidal adverse effects.

Methods/case report

Extrapyramidal symptoms are rarely

reported with clozapine. Although, cases of patients with

clozapine-induced tics have been described. We report the case of

a 28 year-old patient with history of refractory schizophrenia that

developed motor tics with clozapine 150mg total dose. Tics con-

sisted on eye blinking, eyebrow elevation, mouth twitching, facial

grimacing, lip licking, tongue protrusion and shoulder shrugging.

Reduction of clozapine dose to 50mg qd was indicated to decrease

the motor tics, however exacerbation of psychosis occurred.

We added amisulpride and titrated it up to 600mg qd without

response. By using the same principle of levodopa’s washout in

Parkinson disease and in order to establish a therapeutic threshold,

we conducted a one-week clozapine washout.

Results

After this therapeutic manoeuvre, tics disappeared and

no relapse was observed after clozapine reinitiation along with

remission of psychotic symptoms.

Conclusions

Wash out might be a new strategy for treatment

reinitiation after clozapine induced extrapyramidal side effects in

patientswith treatment-resistant schizophrenia. To our knowledge

no previous report of this strategy has been reported, however

further studies are needed to support its effectiveness.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2160

EV1176

Correlation between childhood

trauma and cognitive impairment in

patients with schizophrenia

J. Mrizak

, R. Trabelsi , A. Arous , A. Aissa , H. Ben Ammar ,

Z. El Hechmi

Razi Hospital, Psychiatry F, Mannouba, Tunisia

Corresponding author.

Introduction

Abusive childhood experiences are claimed to be

more prevalent in people with schizophrenia (SCZ) than in the

general population. The exposure to childhood trauma can have

adverse effects on cognitive function.

Objectives

To investigatewhether there is a relationship between

childhood trauma (CT) and cognitive functioning in patients with

SCZ.

Methods

Fifty-eight outpatients with stable SCZ were recruited.

The participants completed the Childhood Trauma Questionnaire

retrospectively assessing five types of childhood trauma (emo-

tional, physical and sexual abuse, and emotional and physical

neglect). They also completed a neurocognitive battery compris-

ing the following tests: the Hopkins Verbal Learning Test–Revised

(HVLT-R), the Letter Digit Substitution Test (LDST), the Stroop Test

(ST), the “Double Barrage” of Zazzo (DBZ), the Modified Card Sort-

ing Test (MCST), the Verbal Fluency (VF), the Trail Making Test-Part

A (TMT-A) and the Digit Span (DS).

Results

The patients with a history of physical abuse (

P

= 0.03)

or emotional neglect (

P

= 0.07) performed worse at the delayed

recall of the HVLT-R. A history of emotional neglect was also corre-

lated to a significantlyworse performance in theTMT-A (

P

< 0.0001),

while physical abuse was correlated to worse DS (

P

= 0.015). High

emotional abuse scores were significantly correlated to poorer effi-

ciency in DBZ (

P

= 0.025).

Conclusions

The results need replication, but underline the

necessity of investigating biological and psychosocial mechanisms

underlying these subjects’ cognitive impairment.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2161

EV1177

Schizophrenia and sexual

desinhibition

M. Palomo Monge

1 ,

, G.M. David

1

, D.D. Arántzazu

2

,

A.L. Maria Fernanda

3

, T.G. Maria Fernanda

1

, M.M. Gemma

3

,

D.C. Sandra

4

1

Hospital Nuestra Se˜nora del Prado, Psychiatry, 45600 Spain

2

Hospital General de Avila, Psychiatry, Avila, Spain

3

Hospital Nuestra Se˜nora del Prado, Family Medicine, Talavera de la

Reina, Spain